C7B.8 — Other secondary neuroendocrine tumors
Is C7B.8 billable?
Yes — C7B.8 is billable for FY2027. C7B.8 is a valid, billable ICD-10-CM code at the highest level of specificity in its branch. C7B.8 may be submitted for encounters from October 1, 2026 through September 30, 2027.
C7B.8 at a glance
| Code | C7B.8 |
|---|---|
| Description | Other secondary neuroendocrine tumors |
| Billable | Yes |
| Code set | ICD-10-CM FY2027 |
| Valid for encounters | October 1, 2026 – September 30, 2027 |
Which MS-DRGs does C7B.8 group to?
C7B.8 sits in MDC 17 and helps define the logic of 3 MS-DRGs (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.
- 826Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCCsurgical
- 827Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CCsurgical
- 828Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCCsurgical
As a secondary diagnosis, C7B.8 is a complication or comorbidity (CC), which can move a stay into a higher-paying DRG.
How is C7B.8 listed in the Alphabetic Index?
These are the routes through the Alphabetic Index that lead to C7B.8. They show the wording a clinician may have documented, which often differs from the Tabular description.
- Tumor › neuroendocrine › secondary NEC
- Tumor › secondary › neuroendocrine NEC
Use additional code — inherited from C7B
Report an additional code alongside C7B.8 to fully describe the condition. C7B.8 is sequenced first.
- code to identify any functional activity
How long has C7B.8 existed?
C7B.8 has been in ICD-10-CM since at least FY2016, the earliest fiscal year on record here.
Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.